Danish pharmaceutical company Novo Nordisk — best known for its blockbuster weight-loss drugs Ozempic and Wegovy — has signed ...

In the years leading up to its bankruptcy filing, the company also struggled with the growth of free or low-cost ...

Pedersen and Maggie Fick COPENHAGEN/LONDON (Reuters) -Obesity drugmaker Novo Nordisk downgraded its 2025 sales forecast on ...

Following on from a remarkable study in mice, scientists have now confirmed that silencing a certain protein in muscle tissue ...

Shares of the company, which once boasted of media mogul Oprah Winfrey as one of its top shareholders, slumped 40% in ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

The obesity drug price wars are finally starting. After being publicly lambasted for the high cost of their weight-loss shots ...

Founded in 1963 by Jean Nidetch, WeightWatchers began as a weekly weight-loss support group with just 400 attendees. It quickly grew into a global phenomenon, attracting millions of members worldwide ...

Nutritional counseling remains a central component of obesity treatment, even in the era of highly effective weight-loss ...

Physicians describe common prior authorization challenges when treating patients for obesity and share strategies to overcome ...

The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. The head of Zealand Pharma has called its $5.3bn partnership with Roche to commercialise an obesity drug ...